NCT05401643 is a NA clinical trial of Xemio mobile application in Breast Cancer, sponsored by Fundacion Clinic per a la Recerca Biomédica.

Who is sponsoring NCT05401643?

NCT05401643 is sponsored by Fundacion Clinic per a la Recerca Biomédica.

What drugs are being tested in NCT05401643?

Interventions in NCT05401643: Xemio mobile application.

What condition does NCT05401643 study?

NCT05401643 studies Breast Cancer, Breast Neoplasms, Quality of Life, Survivorship.

Is NCT05401643 still recruiting?

NCT05401643 is currently completed. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT05401643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors

Completed NA Last updated 28 February 2024

What this trial tests

NA trial testing Xemio mobile application in Breast Cancer in 110 participants. Completed in 30 June 2023.

Timeline

1 November 2020

Primary endpoint
30 November 2022

30 June 2023

Quick facts

Lead sponsor	Fundacion Clinic per a la Recerca Biomédica
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	110
Start date	1 November 2020
Primary completion	30 November 2022
Estimated completion	30 June 2023
Sites	1 location across Spain

Drugs / interventions tested

Xemio mobile application

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Breast Neoplasms — all drugs for Breast Neoplasms →
Quality of Life — all drugs for Quality of Life →
Survivorship — all drugs for Survivorship →

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Who can join

18 and older, female only, with Breast Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

mACMA is a pilot study that is developed for breast cancer survivors of the Hospital Clinic of Barcelona. The objective of this study is to evaluate the progress in quality of life through the introduction of a mobile phone App that allows for symptom tracking, physical activity tracking and a calendar of patient-oriented events organized by patient organizations. This study is a two-arm randomized clinical trial. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 875351.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL).
Fuentes-Expósito MA, Frid S, Muñoz-Mateu M, Sisó-Almirall A, et al · · 2026 · PMID 42127092 · DOI 10.1371/journal.pone.0342702

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Fundacion Clinic per a la Recerca Biomédica trials

Trials by the same sponsor.

NCT07454096 — Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study · Phase 4 · not yet recruiting
NCT07412873 — Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer · Phase 4 · not yet recruiting
NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
NCT07105384 — Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear · Phase 2 · active not recruiting
NCT06896617 — Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05401643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacion Clinic per a la Recerca Biomédica
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05401643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing